Chemical Treatment for Osteoporosis


Executive Summary


In the United States alone, 10 million people are afflicted, and 18 million more are at risk of developing the bone disease, osteoporosis. The large market for osteoporosis treatments and the fact that currently available therapeutics have the potential to produce severe negative side effects or are required to be administered via injection. This demonstrates the need for new therapeutics that overcome these challenges.


Description of Technology


This technology uses high molecular weight polyethylene glycol (HMW-PEG) to treat osteoporosis. HMW-PEG has been previously shown to enhance GI mucinous and cytoskeletal barriers that prevent pathogenic gut bacteria from interacting with or invading the gut wall at points of weakness leading to systemic inflammation. Inflammation  has been linked to bone loss leading to osteoporosis. Here, the inventor has demonstrated that HMW-PEG has positive effects on bone formation in mice.


Key Benefits

  • Minimal side effects
  • Easy delivery—orally taken
  • Promotes bone formation 



  • Osteoporosis treatment
  • Bone degeneration conditions


Patent Status:




Licensing Rights Available


Non-exclusive rights


Inventors: Laura McCabe, Rifat Pamukcu


Tech ID: TEC2013-0086


Alternative contact due to temporary leave:


Nina (Isi) Davis, Technology Marketing Manager, email:, phone (direct): (517)884-1829. 


Patent Information:

For Information, Contact:

Randy Ramharack
Technology Manager
Michigan State University